Breast Cancer | Specialty

Low Recurrence Score in Breast Cancer Shows No Survival Benefit With Chemo Plus Hormonal Therapy

July 28th 2016

Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.

Dual HER2-Targeted Approach Delivers Greatest Neoadjuvant Benefit in HER2+ Breast Cancer

July 28th 2016

In terms of neoadjuvant therapies for patients with HER2-positive breast cancer, dual anti–HER2-directed agents seem to have the most benefit.

Dr. Sparano on the Role of Endocrine Therapy in Breast Cancer

July 27th 2016

Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer.

Less Treatment May Show Greater Benefit in Low-Risk Breast Cancer

July 27th 2016

Although there has been in increase in promising novel regimens available for patients with breast cancer in recent years, oncologists should carefully consider whether each agent would provide a significant enough benefit to offset its associated toxicities, cost, and the time and commitment by the patient it requires.

Expert Shares How Neoadjuvant Trials for TNBC Will Improve Treatment Decisions

July 25th 2016

Recent findings from clinical trials exploring neoadjuvant treatment in patients with triple-negative breast cancer may provide answers to several questions surrounding early-stage disease.

Neratinib Benefit in Breast Cancer Sustained in 5-Year ExteNET Analysis

July 22nd 2016

A 5-year assessment showed that neratinib reduced the risk of invasive disease recurrence or death by 26% compared with placebo as extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Discussing Palliative Care Plans Earlier Improves Quality of Life

July 21st 2016

A team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.

Steroid Mouthwash May Prevent Stomatitis in Some Breast Cancer Patients

July 21st 2016

A study of women treated with the mTOR inhibitor everolimus (Afinitor) plus exemestane for their advanced breast cancer found that daily use of a steroid-based mouthwash markedly decreased the incidence and severity of stomatitis.

Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer

July 20th 2016

Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

Dr. Rugo on SWISH Trial for HR-Positive Breast Cancer

July 18th 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Hellen Diller Family Comprehensive Cancer Center, discusses the results of the SWISH trial, which examined a dexamethasone-based mouthwash for the prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Risks for Breast, Ovarian Cancers Could Be Found With Multigene Panel Testing

July 14th 2016

Allison W. Kurian, MD, MSc, discusses 2 clinical trials utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Dr. Blum on Takeaways from ABC Trials for Breast Cancer

July 14th 2016

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.

Dr. Nicholas Robert on MA.17R Trial for Patients With Early-Stage Breast Cancer

July 13th 2016

Nicholas J. Robert, MD, medical oncology, hematology, Virginia Cancer Specialists, US Oncology, discusses the MA.17R trial, which explored an extension of adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer

July 12th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.

Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

July 9th 2016

CDK4/6 Inhibitor Shows Promise as Single Agent in HR+ Breast Cancer

July 6th 2016

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

Expert Shares Insight on Improved DFS With TaxAC in HER2-Negative Breast Cancer

July 5th 2016

Joanne L. Blum, MD, PhD, discusses the design and phase III results from the ABC trials, and what impact the encouraging findings could have in patients with HER2-negative breast cancer.

Dr. Kuerer on Challenges With Treating DCIS

June 30th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

June 29th 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

Dr. Hughes on RT in Elderly Patients With ER+ Breast Cancer

June 28th 2016

Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.